Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

An estimated 7.2 million Americans aged 65 years and older are living with Alzheimer dementia, and almost all adults feel it is important to diagnose the disease early.

Since then, other amyloid-targeting monoclonal antibodies, lecanemab and donanemab, have been approved by the US Food and Drug Administration (FDA) for early Alzheimer’s disease. 3 Importantly ...